DMAC - Earnings call transcript Q4 2018 | DiaMedica Therapeutics Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the DiaMedica Corporate Update and 2018 Financial Results Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at diamedica.com in the Investor sector.

Before the Company proceeds with these remarks, please note that the Company will be making forward-looking statement on today’s call. These statements are subject to risk and uncertainties that could cause results to differ materially from those projected in these statements. More information appears in the section entitled cautionary statement regarding forward-looking statements in the Company’s press release and under the heading Risk Factors in DiaMedica's recent filed and report in Form 10-K. available and are at its filings diamedica.com. SEC at on www.sec.gov website DiaMedica's that on may comments only also reviewing. of any Please note or replay made accurate the today transcript XX, any webcast be as March today's XXXX longer and no at time of speak call

Following DiaMedica's introduce up for your questions. the today's will President would I call call remarks, the we Pauls, and host CEO. now prepared Rick open for like to

You may begin.

Rick Pauls

joined section Financial like be options to the can DiaMedica's this and first listed opportunity on the brief treatment on ischemic of www.diamedica.com. our Chris, a today Thank these stroke. past we on good up-to-date a and we kidney We made privilege annual and release background summary the limited these this the acute our we've treatment Welcome to DiaMedica disease our both appreciate everyone tremendous doctors class where XX-K, issued and call and there a believe begin morning very year. NASDAQ conference you, company. filed progress to Officer, DiaMedica. Yesterday, to of medicine everyone. Form as with speak morning a investor of the found become a It’s new bring at with treating a to chronic website for I’m to Scott which for Kellen. everyone and DMXXX would this today potential Certainly, that protein report Chief results our has of symptoms. are I of limited press call are patients on with these

component blood the Tissue our protein, bodies key increase manufactured a is regulate produces patients suffering for it flow of acute from We KLKX DMXXX or to stroke. and conducting currently is called disease Kallikrein have or of successfully protein of This synthetic to studies key DMXXX We this a human and which for flow. blood kidney version body the decrease or CKD clinical protein and synthesized required. call ischemic as treatment microvascular we’re and chronic

As diminished. In stroke with flow. CKD to we body's help blood lack believe us we may from of patients age, produce tissue KLKX organ and ability flow grow DMXXX to blood body’s treatment to our be and ability summary, will suffer the regulate

For kidney the in physiology avoid of a order the ultimately to preserve and patients, disease dialysis. function DMXXX has the for maintain kidneys to delay or potential ideally need

companies stroke. after believe less more window ischemic is stroke after hours than stroke, will limited standard of today. TPA improve a give the none current with doctors four we in are DMXXX to limited receiving a sourced two treatment there. protein is of currently I are like large our two also over Asia have are forms human pancreas today. they KLKX by in treated of believe forms to pharmaceutical there the then been several pigs. marketed used therapeutic XX with patient For This After on TPA and would patients, available of patients Asia, which treatment and millions XX% being care stroke after are These highlight of acute we based this urine research could patients and where starting recovery than from hours the post-stroke no that option

protein this form KLKX critical depleted replacement of use are therapy synthetic for positioning protein. its worldwide levels to in DMXXX a We restore as

submitted we We and and insulin of now trial, at treatment which in this patients a by clinical looking open-label the replaced DMXXX attempting patients FDA, evaluate subcutaneous an and study enrolling been moderate Genentech in in levels the with in goals dose DMXXX porcine IND a that both an development begin in-person sites XX at U.S. ultimately Phase year three insulin U.S. synthetic designed is way doses, XXXX, include with last to we ratio successfully the Another advancing safety of three for Phase levels development CKD. DiaMedica we've Ib programs. in IND conducted trials. made administered replace our DMXXX patients period. This This In progress single the meeting all to early In CKD After in for Lilly. the the porcine was ischemic kidney has clinical an accepted commence past over dose in This achieved way biomarkers, significant December important pharmacokinetics, KLKX assist in to and severe include study identifying Phase change points acute with in subsequent of will end are KLKX, in stroke. was we XXXX, creatinine year, those pipeline. CKD has use levels, albumin study III II measured tolerability, a Primary in and XX-day or to other us in of

mid-XXXX. in We out to the expect of the results read CKD study on

rare planning II XXXX. of chronic disease with in in of study initiated half Phase forms be second We’re randomized the currently patients a to kidney

and We this follow. will target others be rare study to update to on details forms in these

Turning patients. in markers XXXX. in acute we is REMEDY tolerability safety, placebo-controlled our Phase ischemic our DMXXX progress with This the stroke designed trial a assess of to double-blinded, stroke, and begin patients to study, II enrolling randomized in

patients, also robust data IPO, to we've the of patients, With This from to XX studies. raised potential. design to will study DMXXX XXX support hope enrollment multiple and to to tests up of efficient Phase our U.S. success the III provide the we include therapeutic increasing with investigate recent target additional

fourth as trial XXXX, described. Given quarter the of increase previously in of or enrollment XXXX to this target, the we expect complete quarter first in

U.S. sufficient as suffering build XXXX have in disease clinical to we December, of have Phase our which our to programs. ischemic the IPO success hold patient kidney expect we potential work pipelines in programs, to impact we chronic towards lead significant on We upon advancing After from successful and our obtain listing acute II NASDAQ our and believe stroke. capital in read-outs two

to the next in milestones We are we achieve year development well look meaningful our and progress. our to positioned sharing clinical to execute forward plans on

Disorders. of Human our Therapeutic Kallikrein in Turning Tissue this the year, developments, Neurological using literature mechanistic the stroke Advances other journals, KLKX titled, covering announced KLKX paper to in presents treatment published January the for an of This role treatment the acute peer-reviewed as in ischemic was we pharmacological additional rationale ischemic biochemical and in of manuscript for scientific that reviews acute stroke.

website treatment in from supporting of the KLKX of from clinical of of is addition Advisory that’s of potential been In and on on paper This disease ischemia. been and provide has form patients our expanding white KLKX ischemic for models plan involving been to of and available results KLKX, the biochemical least the acute is therapeutic Today, has results mechanism hypotheses Advisory animal an published and to urine we demonstrating treatment form on reasons in and to-date China isolated the summarizes clinical Board treatment from acute genetics urine in the benefits use post-infarct The paper this to We The ischemic been candidate series offers with patients of product preclinical for the information the and have further our KLKX/DMXXX the patients of disease. stroke the chronic testable over also details isolated chronic published to also our patients. stroke form treat follow pig we stroke for that of white of for kidney long-term this at in It protein. today on reviews with Scientific chronic paper kidney brain shortly by XXX,XXX treated update effect approved X,XXX a for believe highlights data trials also clinical Asia Stroke ischemic acute human released the pancreas. Asia. assembled under protein Shortly, this kidney human disease paper action. Board.

a development Scott years with past the highlight patients Harry turning treating the kidney review Officer. standing I'd Research call some the he results, the like Officer. brings also Before year. as extensive XXXX, financial the disease. XX kidney Medical appointment in Harry's designed provides in Scientific chronic community over Dr. at in with clinical Chief served DaVita on as research Alcorn of while has community development. DiaMedica clinical experience of Alcorn disease conducting of as personnel Dr. principal on leads in kidney announced trials kidney and to Chief review the over In prospective Dr. to of the unique clinical this their Alcorn Clinical him focus we as investigator global experience with our studies hundreds to chronic with

has He added Operating years Financial recent experience of in with public healthcare significant will instrumental to Scott science Officer corporate he over summary full multiple provide Scott financials and of NASDAQ that, for early-stage IPO. Scott capital of life over of Officer as and as now a Chief I With year Kellen XX was has within call Officer. course Financial quarter and publicly traded we companies, positioned and our XXXX. our external experience XXXX, formation, was turn Chief fourth to private reporting the our with Chief and companies. governance the in Additionally

Scott Kellen

Rick. Thank you,

was States December for straight strengthened obtain proceeds on our First investor balance of and we base we Phase the several raised XX.X after that clinical million And financial our indicated, offering, institutional stroke. gave the we Yesterday, and gross our and speaking as and the reported us and an Capital Xth listing we sheet. II it IPO, results a concurrently capital both cost we This for NASDAQ us expanded adding common milestone In in IPO, Market. Rick XX.X investors trials netted both complete shares to the CKD XXXX. in million. this important United in completed U.S.

million was to Our XXXX. loss a X.X compared net loss or for for net share, $X.XX XX% year or per of million per X.X the share

was in we of the no with Fosun agreement Ahon revenue Our the of collaboration XXXX Pharma September comprised during a signed in we initial year and payments had revenue $XXX,XXX license we license connection for subsidiary last received and Pharmaceuticals, XXXX. of with

of to our which million was cost. drug XXXX, XXXX and II FDA, related in cost investigational to and the cost for increased Phase in compensation stroke the completed personnel from study, Our expenses with compared the and development study X.X to X.X bridging new the substantially preclinical due stock-based was additional REMEDY application DMXXX non-cash increase research as increase to U.S XXXX. The study million X.X higher testing million increased for support required and an primarily

to salaries, X.X and listing contributed and Our short-term the of fees. cost fees benefits to X.X due legal for compensation related associated incurred one-time share-based during staff and general and administrative IPO, to XXXX and U.S. planned process due Company's XXXX. primarily the addition also These NASDAQ higher to cost increase Higher XXXX. were with million accounting increased the to compared the million a expenses in related

XXXX in year was research currency partially in the that, and for I'll compared full performed over Our the XXXX.So finished are paid increase cash and recognition turn resulted at the government. to foreign the of the The XX, is the the the primarily through with XXX,XXX XXXX. Australian offset Australia. work other our from we by year to transaction losses qualifying with we X.X DiaMedica XX.X incentives for from increase end income fund receivables of back operations This million for XXXX. And million to These research Rick. which by XXXX, during expect increased December of call development

Rick Pauls

Scott. Thanks,

support III had DiaMedica. studies our for questions. will open could time our and disease XXXX remarks the II chronic now be kidney to for positive ask up a critical So lines ischemic I Phase data This a Phase our concludes acute the operator and prepared XXXX for studies. transformative potential stroke clinical and from transition to Its

Operator

Nowak And with comes first [Operator question Instructions] of Craig-Hallum our Alex from the you. Thank Capital. line

open. is now line Your

Alex Nowak

trial? Scott how REMEDY REMEDY? recent Rick you the in Congrats through for Rick, are recruiting both and then enrollment on sites How actively looks the and is patients for IPO. sites recruiting like enrolled us trial both for are currently how all three many CKD in many in are trial, could tracking here up-listing the walk the kidney

Rick Pauls

Right, track listing so, within next read-out year. the II on Phase we’re the data still

of in terms been guidance patients specific formal of We enrolled. the haven’t provided that number have

the our kidney chronic of this in the to that We Ib, half we and initiate second us Phase study complete II year. summer, the believe will this to allow expect disease Phase

clinical stroke we have with on Phase that the We And still sites track CKD are running up three timelines. the II on the and side, on are study.

data line We this up and sites XX and of top expect in today, QX running we have XXXX. report year QX this to or

Alex Nowak

went two paper, at any been good of strategic, paper has of the hear, any live. almost then KLKX on Okay where you’re provoked perhaps science out additional Can publishing months comments with and around of KLKX what recent It's stroke. And use useful? DMXXX areas reactions to there? anyone congrats acute you paper sort looking the be could ischemic supporting from the peer-reviewed first since and the conversations getting the form larger community synthetic other provide

Rick Pauls

of definitely, understood. protein the nice has well very aspect paper used important it’s in particular is Asia this review how this So, in and received. The aspect been of not been well today

kidney form on yesterday. pharma, had we we've ways but are one acute those that. at have with discussions the response big paper these for have to works really the paper then, regard excited clinical the chronic So, porcine do treated to use protein ischemic how I'd And we’re mean, summarize out very to of this With is today, been I positive comments no stroke. protein in disease, this starting we get patients say literally and mechanism least XXX,XXX the

great the protein I kidney document KLKX a China. believe millions been in in how of that using patients one now has crude been for understand to protein used opportunity have think has and of people literally Japan the form been for disease. there porcine really it's KLKX We

Alex Nowak

just having II this With the your the And enough read-outs. Phase trial get trials, ongoing stroke confident mentioned usage. to question of cash Phase a cash launch and kidney then then Phase you've Scott through later on Ib both II the and

what of -- to does get incremental are that milestone Phase wrap for you trials cash your in lined any So total when cash thinking. up? II Pharma? And model does payments total both just your -- What modeling with up Ahon from include my the

Scott Kellen

variable predict the It’s given it's hard the studies. Again, nature these cash. of to of timing the

upon to think split like maybe And terms, be of to data on a I of inclusion was bit XX/XX II Phase not year the to complete still the no, milestone. the react left and terms IPO of have so, in the year. somebody is in some goal that’s able And a based answer runway else's. our whole versus not this And short the next

be but work our to will get a building we done with that the So, have. when nice comes, our study resources it we’re plan add

Alex Nowak

trial on just question then should and update begin Pharma that, in China? last And And touching their stroke me just expect from on III we when Rick, Ahon and the partnership? enrolling any Phase

Rick Pauls

that take Scott, do you to want one.

Scott Kellen

of over there. their through as process They But design Alex, path they the down help process. documents, non-clinical information our move Sure, the to job still has support translation the have they through been regulatory of to terms to of application. under support dossier them and agreement, them nail need the with some agreed our relative expeditiously all possible the test as and the to preparation

those FDA. to take. developed based very so discussions how the applying, they that to And while want on they timing have the go, we'll believe close ultimately we course be will are the decide of upon what in they their to then Chinese depending with And

predict to us they enrolling for patients. hard when start really it's So, will actually

Operator

would back President like [Operator does the to for you. Paul, Rick CEO Instructions] remarks. to Mr. conclude further I And turn call any session. now that question-and-answer today's Thank and

Rick Pauls

and you for dedication Thank for all the support continued DiaMedica.

is to is appreciate We support for develop making Thank treatments Our serious and novel call. treatment neurological diseases mission in novel much. for to take and of community very I medical bring pride shareholders accomplishments concludes diseases. our truly your DiaMedica these treatments very disorders, of this hope in and kidney continued that and driving progress. our and a to interest you we're

Operator

today's today's for conference. participating gentlemen, in does Ladies conclude program. thank This you the and

disconnect. day. You may all great a Everyone have

DiaMedica Therapeutics (DMAC) 20 Mar 192018 Q4 Earnings call transcript